Bank of New York Mellon Corp Boosts Holdings in Evolus, Inc. (NASDAQ:EOLS)

Bank of New York Mellon Corp raised its holdings in Evolus, Inc. (NASDAQ:EOLSFree Report) by 12.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 164,020 shares of the company’s stock after purchasing an additional 17,999 shares during the quarter. Bank of New York Mellon Corp owned about 0.29% of Evolus worth $1,499,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in EOLS. SG Americas Securities LLC purchased a new stake in Evolus during the 3rd quarter valued at approximately $171,000. Global Retirement Partners LLC lifted its holdings in shares of Evolus by 888.6% during the third quarter. Global Retirement Partners LLC now owns 8,650 shares of the company’s stock worth $73,000 after purchasing an additional 7,775 shares during the period. Legato Capital Management LLC grew its position in Evolus by 7.3% in the 3rd quarter. Legato Capital Management LLC now owns 110,329 shares of the company’s stock valued at $1,008,000 after buying an additional 7,542 shares during the last quarter. California State Teachers Retirement System increased its stake in Evolus by 12.6% in the 2nd quarter. California State Teachers Retirement System now owns 50,990 shares of the company’s stock valued at $371,000 after buying an additional 5,706 shares during the period. Finally, Alliancebernstein L.P. raised its position in Evolus by 25.4% during the 2nd quarter. Alliancebernstein L.P. now owns 64,960 shares of the company’s stock worth $472,000 after buying an additional 13,160 shares during the last quarter. 65.15% of the stock is owned by hedge funds and other institutional investors.

Evolus Trading Up 0.8 %

NASDAQ:EOLS opened at $13.15 on Thursday. The company has a market capitalization of $752.18 million, a P/E ratio of -11.85 and a beta of 1.50. The firm has a 50-day moving average price of $10.86 and a two-hundred day moving average price of $9.65. Evolus, Inc. has a twelve month low of $7.07 and a twelve month high of $13.74.

Evolus (NASDAQ:EOLSGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.26) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.26). Evolus had a negative net margin of 34.11% and a negative return on equity of 507.42%. The business had revenue of $50.02 million during the quarter, compared to analysts’ expectations of $43.72 million. On average, equities research analysts predict that Evolus, Inc. will post -0.79 earnings per share for the current year.

Insiders Place Their Bets

In other Evolus news, Director Karah Herdman Parschauer sold 11,931 shares of Evolus stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $13.14, for a total value of $156,773.34. Following the completion of the sale, the director now owns 31,243 shares in the company, valued at approximately $410,533.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider David Moatazedi sold 31,300 shares of the stock in a transaction on Friday, December 8th. The shares were sold at an average price of $9.73, for a total value of $304,549.00. Following the completion of the sale, the insider now owns 603,944 shares of the company’s stock, valued at $5,876,375.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karah Herdman Parschauer sold 11,931 shares of the firm’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total transaction of $156,773.34. Following the completion of the transaction, the director now directly owns 31,243 shares in the company, valued at approximately $410,533.02. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,579 shares of company stock valued at $979,424. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, December 20th. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $16.00 in a research note on Monday, January 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, January 17th.

Check Out Our Latest Stock Analysis on Evolus

Evolus Profile

(Free Report)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.